Market capitalization | $1.25m |
Enterprise Value | $-11.06m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.39 |
P/B ratio (TTM) P/B ratio | 0.13 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-13.13m |
Free Cash Flow (TTM) Free Cash Flow | $-7.95m |
Cash position | $12.31m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast CohBar Inc:
1 Analyst has issued a forecast CohBar Inc:
Jun '23 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.10 -0.10 |
23%
23%
|
|
EBITDA | -13 -13 |
8%
8%
|
EBIT (Operating Income) EBIT | -13 -13 |
8%
8%
|
Net Profit | -13 -13 |
4%
4%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
CohBar, Inc. engages in the research and development of mitochondria-based therapeutics. It focuses on treatments of diseases, which include diabetes, obesity, fatty liver disease and non-alcoholic steatohepatitis, cancer, Alzheimer's disease, and atherosclerosis. The company was founded by Nir Barzilai, Pinchas Cohen, David Sinclair, John Amatruda, and Laura Cobb on October 19, 2007 and is headquartered in Menlo Park, CA.
Head office | United States |
CEO | Joseph Sarret |
Employees | 10 |
Founded | 2007 |
Website | www.cohbar.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.